Back to top
more

CorMedix (CRMD)

(Delayed Data from NSDQ)

$5.44 USD

5.44
731,887

+0.03 (0.55%)

Updated Apr 17, 2024 04:00 PM ET

After-Market: $5.44 0.00 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy18.00%
3Hold9.44%
4Sell5.10%
5Strong Sell2.53%
S&P50011.08%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value F Growth D Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 33% (82 out of 251)

Industry: Medical - Biomedical and Genetics

Better trading starts here.

Zacks News

Wall Street Analysts Predict a 146.21% Upside in CorMedix (CRMD): Here's What You Should Know

The mean of analysts' price targets for CorMedix (CRMD) points to a 146.2% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Here's Why CorMedix (CRMD) Looks Ripe for Bottom Fishing

After losing some value lately, a hammer chart pattern has been formed for CorMedix (CRMD), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term.

How Much Upside is Left in CorMedix (CRMD)? Wall Street Analysts Think 198.21%

The average of price targets set by Wall Street analysts indicates a potential upside of 198.2% in CorMedix (CRMD). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Cidara Therapeutics (CDTX) Reports Q4 Loss, Misses Revenue Estimates

Cidara Therapeutics (CDTX) delivered earnings and revenue surprises of -1,800% and 45.06%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Pliant Therapeutics, Inc. (PLRX) Reports Q4 Loss, Tops Revenue Estimates

Pliant Therapeutics, Inc. (PLRX) delivered earnings and revenue surprises of -2.86% and 27.10%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

CorMedix (CRMD) Reports Q1 Loss, Lags Revenue Estimates

CorMedix (CRMD) delivered earnings and revenue surprises of 21.74% and 84%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Adma Biologics (ADMA) Reports Q1 Loss, Tops Revenue Estimates

Adma Biologics (ADMA) delivered earnings and revenue surprises of -25% and 9.82%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

IDEAYA Biosciences, Inc. (IDYA) Reports Q1 Loss, Tops Revenue Estimates

IDEAYA Biosciences, Inc. (IDYA) delivered earnings and revenue surprises of 12.20% and 33.64%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Cytokinetics (CYTK) Reports Q1 Loss, Misses Revenue Estimates

Cytokinetics (CYTK) delivered earnings and revenue surprises of -9.68% and 77.53%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Inhibrx, Inc. (INBX) Soars 15%: Is Further Upside Left in the Stock?

Inhibrx, Inc. (INBX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

CorMedix (CRMD) Reports Q4 Loss, Tops Revenue Estimates

CorMedix (CRMD) delivered earnings and revenue surprises of 9.09% and 40%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Adma Biologics (ADMA) Reports Q4 Loss, Tops Revenue Estimates

Adma Biologics (ADMA) delivered earnings and revenue surprises of 10% and 1.47%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

CorMedix (CRMD) Stock Jumps 14.8%: Will It Continue to Soar?

CorMedix (CRMD) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.

Puma Biotech (PBYI) Q4 Earnings and Revenues Surpass Estimates

Puma Biotech (PBYI) delivered earnings and revenue surprises of 190.91% and 16.14%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Seres Therapeutics (MCRB) Reports Q4 Loss, Lags Revenue Estimates

Seres Therapeutics (MCRB) delivered earnings and revenue surprises of -22.22% and 62.94%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Dynavax Technologies (DVAX) Lags Q4 Earnings and Revenue Estimates

Dynavax Technologies (DVAX) delivered earnings and revenue surprises of -20.29% and 14.84%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

CorMedix (CRMD) Reports Q3 Loss, Tops Revenue Estimates

CorMedix (CRMD) delivered earnings and revenue surprises of -22.22% and 280.00%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

CorMedix (CRMD) May Report Negative Earnings: Know the Trend Ahead of Q3 Release

CorMedix (CRMD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Down 21.2% in 4 Weeks, Here's Why You Should You Buy the Dip in CorMedix (CRMD)

CorMedix (CRMD) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.

CorMedix (CRMD) Reports Q2 Loss, Lags Revenue Estimates

CorMedix (CRMD) delivered earnings and revenue surprises of 33.33% and -89.19%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

Analysts Estimate CorMedix (CRMD) to Report a Decline in Earnings: What to Look Out for

CorMedix (CRMD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

CorMedix (CRMD) Reports Q1 Loss, Tops Revenue Estimates

CorMedix (CRMD) delivered earnings and revenue surprises of -11.11% and 46.67%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

CorMedix (CRMD) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

CorMedix (CRMD) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

CorMedix (CRMD) Reports Q4 Loss, Lags Revenue Estimates

CorMedix (CRMD) delivered earnings and revenue surprises of 17.39% and -11.11%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?

Earnings Preview: CorMedix (CRMD) Q4 Earnings Expected to Decline

CorMedix (CRMD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.